左西孟旦对失代偿性晚期心力衰竭患者循环促炎细胞因子和可溶性凋亡介质的影响。
Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.
作者信息
Parissis John T, Adamopoulos Stamatis, Antoniades Charalambos, Kostakis George, Rigas Antonios, Kyrzopoulos Stamos, Iliodromitis Efstathios, Kremastinos Dimitrios
机构信息
Second Department of Cardiology, Amalia Fleming Hospital, Athens, Greece.
出版信息
Am J Cardiol. 2004 May 15;93(10):1309-12. doi: 10.1016/j.amjcard.2004.01.073.
This randomized, placebo-controlled trial showed that levosimendan administration causes a significant reduction of circulating proinflammatory cytokine interleukin-6 and soluble apoptosis mediators, such as soluble Fas and Fas ligand in patients with decompensated heart failure. These immunomodulatory effects may lead to improvement of symptoms and echocardiographic markers of cardiac contractile performance in these patients.
这项随机、安慰剂对照试验表明，在失代偿性心力衰竭患者中，给予左西孟旦可显著降低循环促炎细胞因子白细胞介素-6以及可溶性凋亡介质，如可溶性Fas和Fas配体。这些免疫调节作用可能会改善这些患者的症状以及心脏收缩功能的超声心动图指标。
Zotero 插件